CARLSBAD, Calif., Oct. 23,
2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq:
TYRA), a clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, today
announced that it will host a conference call and webcast on
October 25, 2024 at 8:00 am ET to share interim clinical results of
TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial
cancer (mUC). These data will be presented in a late-breaking oral
presentation at the 36th EORTC-NCI-AACR (ENA) Symposium
on Molecular Targets and Cancer Therapeutics, being held
October 23-25, 2024, in Barcelona, Spain.
Gary Steinberg, MD, Professor of Urology, Department
of Urology, Rush University Medical
Center, will be joining members of TYRA's management
team on the call and will be available during Q&A.
Conference Call Information
TYRA is hosting a conference call and webcast on October 25, 2024, at 8am
ET to review the interim clinical data demonstrated with
TYRA-300 in mUC. Participants may access a live webcast of the call
and the associated slide presentation on the "For Investors" page
of the TYRA website at https://ir.tyra.bio. To
participate via telephone, please register in advance at
this link. Upon registration, all telephone
participants will receive a confirmation email detailing how to
join the conference call, including the dial-in number along with a
unique passcode and registrant ID that can be used to access the
call. A replay of the conference call and webcast will be archived
on the Company's website for at least 90 days.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on
LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-host-conference-call-on-interim-clinical-data-of-tyra-300-from-surf301-phase-12-study-on-october-25-2024-at-8am-et-302285111.html
SOURCE Tyra Biosciences